Singapore Clinical Trial: A multi-center, open-label, phase I/II study to evaluate the safety and efficacy of asciminib with chemotherapy followed by asciminib plus blinatumomab in pediatric, adolescent, and young adult participants with relapsed or refractory BCR::ABL1-positive (Philadelphia positive, Ph+) or BCR::ABL1-like (Ph-like) acute lymphoblastic leukemia (ALL)

Singapore, Sept. 15 -- The Health Sciences Authority received information related to the study titled 'A multi-center, open-label, phase I/II study to evaluate the safety and efficacy of asciminib wit... Read More

Singapore Clinical Trial: A Phase III, multisite, randomized, double-blind trial of BNT327 in combination with chemotherapy versus placebo with chemotherapy in patients with previously untreated locally recurrent inoperable or metastatic TNBC determined ineligible for PD(L)1 therapy based on PD-L1 negative disease

Singapore, Sept. 15 -- The Health Sciences Authority received information related to the study titled 'A Phase III, multisite, randomized, double-blind trial of BNT327 in combination with chemotherapy... Read More

Clinical Trial: Efficacy Evaluation of Turmeric-Derived Nanoparticle Hydrogel for the Treatment of Diabetic Foot Ulcer Wounds

U.S., Sept. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07818252) titled 'Efficacy Evaluation of Turmeric-Derived Nanoparticle Hydrogel for the Treatment of Diabeti... Read More

Singapore Clinical Trial: A Phase III, multisite, randomized, double-blind trial of BNT327 in combination with chemotherapy versus placebo with chemotherapy in patients with previously untreated locally recurrent inoperable or metastatic TNBC determined ineligible for PD(L)1 therapy based on PD-L1 negative disease

Singapore, Sept. 15 -- The Health Sciences Authority received information related to the study titled 'A Phase III, multisite, randomized, double-blind trial of BNT327 in combination with chemotherapy... Read More

Singapore Clinical Trial: PODOMOUNT-Basket, a Phase II, multicentre, randomised, 2 arm parallel-group, double-blind, placebo-controlled basket trial to assess safety, tolerability, PK, and efficacy of BI 764198 in four proteinuric kidney diseases

Singapore, Sept. 15 -- The Health Sciences Authority received information related to the study titled 'PODOMOUNT-Basket, a Phase II, multicentre, randomised, 2 arm parallel-group, double-blind, placeb... Read More

Singapore Clinical Trial: Bepirovirsen Liver Biopsy study

Singapore, Sept. 15 -- The Health Sciences Authority received information related to the study titled 'Bepirovirsen Liver Biopsy study'. The following are the other relevant details related to the tri... Read More

Clinical Trial: The Variation in Electrode Configuration for Termination of Out-of-Hospital Rhythms That Are Shockable in Cardiac Arrest Trial

U.S., Sept. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07818785) titled 'The Variation in Electrode Configuration for Termination of Out-of-Hospital Rhythms That A... Read More

Singapore Clinical Trial: CA2400030: A Randomized, Phase 2/3 Study Comparing Navlimetostat in Combination with Nab-paclitaxel and Gemcitabine versus Placebo in Combination with Nab-paclitaxel and Gemcitabine in Participants with Untreated Metastatic Pancreatic Ductal Adenocarcinoma Harboring Homozygous MTAP Deletion

Singapore, Sept. 15 -- The Health Sciences Authority received information related to the study titled 'CA2400030: A Randomized, Phase 2/3 Study Comparing Navlimetostat in Combination with Nab-paclitax... Read More

Singapore Clinical Trial: A randomised phase III trial of adjuvant cemiplimab in patients with resected stage IIA-IIIB NSCLC who have not received prior adjuvant chemotherapy

Singapore, Sept. 15 -- The Health Sciences Authority received information related to the study titled 'A randomised phase III trial of adjuvant cemiplimab in patients with resected stage IIA-IIIB NSCL... Read More

Singapore Clinical Trial: Phase 2, Open-Label, Long-Term, Extension (OLE) Study of Infigratinib, an FGFR 1-3-Selective Tyrosine Kinase Inhibitor, in Children with Hypochondroplasia: ACCEL OLE

Singapore, Sept. 15 -- The Health Sciences Authority received information related to the study titled 'Phase 2, Open-Label, Long-Term, Extension (OLE) Study of Infigratinib, an FGFR 1-3-Selective Tyro... Read More

• ««
• «
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• »
• »»